549 related articles for article (PubMed ID: 33266235)
21. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
22. Colon cancer checks in when bile acids check out: the bile acid-nuclear receptor axis in colon cancer.
Tang Q; Evans RM
Essays Biochem; 2021 Dec; 65(6):1015-1024. PubMed ID: 34414429
[TBL] [Abstract][Full Text] [Related]
23. Interactions between bile salts, gut microbiota, and hepatic innate immunity.
Schubert K; Olde Damink SWM; von Bergen M; Schaap FG
Immunol Rev; 2017 Sep; 279(1):23-35. PubMed ID: 28856736
[TBL] [Abstract][Full Text] [Related]
24. Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment.
Zhu L; Baker RD; Zhu R; Baker SS
J Pediatr Gastroenterol Nutr; 2018 Jul; 67(1):3-5. PubMed ID: 29697548
[TBL] [Abstract][Full Text] [Related]
25. Picroside II protects against cholestatic liver injury possibly through activation of farnesoid X receptor.
Li T; Xu L; Zheng R; Wang X; Li L; Ji H; Hu Q
Phytomedicine; 2020 Mar; 68():153153. PubMed ID: 32018210
[TBL] [Abstract][Full Text] [Related]
26. Role of Bile Acids in Metabolic Control.
Molinaro A; Wahlström A; Marschall HU
Trends Endocrinol Metab; 2018 Jan; 29(1):31-41. PubMed ID: 29195686
[TBL] [Abstract][Full Text] [Related]
27. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease.
Pereira-Fantini PM; Lapthorne S; Joyce SA; Dellios NL; Wilson G; Fouhy F; Thomas SL; Scurr M; Hill C; Gahan CG; Cotter PD; Fuller PJ; Hardikar W; Bines JE
J Hepatol; 2014 Nov; 61(5):1115-25. PubMed ID: 24999016
[TBL] [Abstract][Full Text] [Related]
28. Bile Acids Activated Receptors Regulate Innate Immunity.
Fiorucci S; Biagioli M; Zampella A; Distrutti E
Front Immunol; 2018; 9():1853. PubMed ID: 30150987
[TBL] [Abstract][Full Text] [Related]
29. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.
Baghdasaryan A; Claudel T; Gumhold J; Silbert D; Adorini L; Roda A; Vecchiotti S; Gonzalez FJ; Schoonjans K; Strazzabosco M; Fickert P; Trauner M
Hepatology; 2011 Oct; 54(4):1303-12. PubMed ID: 22006858
[TBL] [Abstract][Full Text] [Related]
30. Cross-talk between bile acids and intestinal microbiota in host metabolism and health.
Nie YF; Hu J; Yan XH
J Zhejiang Univ Sci B; 2015 Jun; 16(6):436-46. PubMed ID: 26055905
[TBL] [Abstract][Full Text] [Related]
31. Bile Acid Metabolism in Liver Pathobiology.
Chiang JYL; Ferrell JM
Gene Expr; 2018 May; 18(2):71-87. PubMed ID: 29325602
[TBL] [Abstract][Full Text] [Related]
32. Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
Reich M; Klindt C; Deutschmann K; Spomer L; Häussinger D; Keitel V
Dig Dis; 2017; 35(3):235-240. PubMed ID: 28249265
[TBL] [Abstract][Full Text] [Related]
33. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice.
Zheng X; Huang F; Zhao A; Lei S; Zhang Y; Xie G; Chen T; Qu C; Rajani C; Dong B; Li D; Jia W
BMC Biol; 2017 Dec; 15(1):120. PubMed ID: 29241453
[TBL] [Abstract][Full Text] [Related]
34. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity.
Münzker J; Haase N; Till A; Sucher R; Haange SB; Nemetschke L; Gnad T; Jäger E; Chen J; Riede SJ; Chakaroun R; Massier L; Kovacs P; Ost M; Rolle-Kampczyk U; Jehmlich N; Weiner J; Heiker JT; Klöting N; Seeger G; Morawski M; Keitel V; Pfeifer A; von Bergen M; Heeren J; Krügel U; Fenske WK
Microbiome; 2022 Jun; 10(1):96. PubMed ID: 35739571
[TBL] [Abstract][Full Text] [Related]
35. Endocrine and paracrine role of bile acids.
Keitel V; Kubitz R; Häussinger D
World J Gastroenterol; 2008 Oct; 14(37):5620-9. PubMed ID: 18837077
[TBL] [Abstract][Full Text] [Related]
36. Bile Acids and Portal Hypertension.
Arab JP; Barrera F; Arrese M
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s83-s86. PubMed ID: 29080345
[TBL] [Abstract][Full Text] [Related]
37. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
Chiang JYL; Ferrell JM
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
[TBL] [Abstract][Full Text] [Related]
38. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation.
Pols TW; Noriega LG; Nomura M; Auwerx J; Schoonjans K
J Hepatol; 2011 Jun; 54(6):1263-72. PubMed ID: 21145931
[TBL] [Abstract][Full Text] [Related]
39. Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease.
Gadaleta RM; van Mil SW; Oldenburg B; Siersema PD; Klomp LW; van Erpecum KJ
Biochim Biophys Acta; 2010 Jul; 1801(7):683-92. PubMed ID: 20399894
[TBL] [Abstract][Full Text] [Related]
40. The Bile Acid Receptor TGR5 and Liver Regeneration.
Jourdainne V; Péan N; Doignon I; Humbert L; Rainteau D; Tordjmann T
Dig Dis; 2015; 33(3):319-26. PubMed ID: 26045264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
